⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025

Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View at Publisher

Ask AI

Bookmark

Share

Key Points

Zilovertamab vedotin shows specific plasma concentration-time profiles after administration, enhancing understanding of dosing efficacy.
Participants receiving zilovertamab vedotin displayed distinct MMAE profiles, indicating the drug's pharmacokinetics in oncology settings.
The phase 2 study explores therapeutic impacts of zilovertamab vedotin in a challenging patient population with few available options.
Data from this study may help optimize future dosing strategies for metastatic solid tumor treatment.

Implication

Phase 2 trial assesses plasma concentration of MMAE in participants with metastatic solid tumors, suggesting potential treatment efficacy.

Abstract

Supplemental Fig S7. Plasma Conc. vs Time Profiles of MMAE in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61b08 https://doi.org/10.1158/2767-9764.30146505

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Fig S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025